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Introduction {#cam41368-sec-0001}
============

Statins are the most widely prescribed cholesterol‐lowering drugs in the United States. According to the latest Centers for Disease Control data in the years 2005--2008, the percent of US adults taking statins had increased to 25% [1](#cam41368-bib-0001){ref-type="ref"} compared to an estimated 11.7% in 2003--2004 [2](#cam41368-bib-0002){ref-type="ref"}. Statins are a class of drugs used for lowering cholesterol and act by competitive inhibition of hydroxy methyl glutaryl coenzyme A (HMG CoA), which is the rate‐limiting enzyme in the mevalonate pathway. Inhibition of the mevalonate pathway also leads to lower levels of downstream products including farnesyl diphosphate (FPP), geranylgeranyl diphosphate (GGPP), and dolichol [3](#cam41368-bib-0003){ref-type="ref"}, [4](#cam41368-bib-0004){ref-type="ref"} which may have implications for chemoprevention of cancer.

Mouse models have demonstrated proapoptotic and antitumor activity of statins against lymphoma [5](#cam41368-bib-0005){ref-type="ref"}. Statins have also been shown to prevent and reverse MYC‐induced lymphoma [6](#cam41368-bib-0006){ref-type="ref"}. In addition, the anti‐inflammatory effect of statins may be an important mechanism of reduction in risk of lymphoma as chronic inflammation may be a risk factor [7](#cam41368-bib-0007){ref-type="ref"}.

Epidemiological studies of the association of statins and risk of lymphoid malignancies have shown mixed results with some studies showing lower risk [8](#cam41368-bib-0008){ref-type="ref"}, [9](#cam41368-bib-0009){ref-type="ref"}, [10](#cam41368-bib-0010){ref-type="ref"} while others showing increased risk or no association [11](#cam41368-bib-0011){ref-type="ref"}, [12](#cam41368-bib-0012){ref-type="ref"}. Statin use and its association with solid malignancies has been extensively studied in the Womens Health Initiative cohort [13](#cam41368-bib-0013){ref-type="ref"}, [14](#cam41368-bib-0014){ref-type="ref"}, [15](#cam41368-bib-0015){ref-type="ref"}. In this report, we analyze the relationship between statin use, statin type, potency, and lipophilicity with risk of NHL overall and NHL subtypes in a large, multisite cohort of postmenopausal women.

Methods {#cam41368-sec-0002}
=======

Study population {#cam41368-sec-0003}
----------------

The study population included 161,808 postmenopausal women aged 50 to 79 enrolled in the Women\'s Health Initiative (WHI) Clinical Trial (CT) and Observational Study (OS) from October 1, 1993 to December 31, 1998. Study implementation details have been published previously [16](#cam41368-bib-0016){ref-type="ref"}, [17](#cam41368-bib-0017){ref-type="ref"}, [18](#cam41368-bib-0018){ref-type="ref"}. Follow‐up continued from study initiation until planned termination in March, 2005, and thereafter for participants providing reconsent. The data collection for the current analysis was updated through September 2012. Some women continue to be followed in the extension study. We excluded women from the analysis who had a prior history of lymphoma (*n* = 243) and for whom there was no information on statin use (*n* = 2) for a final analysis cohort of 161,563.

Statin exposure {#cam41368-sec-0004}
---------------

Statin use was defined as use of any HMG CoA reductase inhibitor. Statins were classified as lipophilic (lovastatin, simvastatin, fluvastatin, atorvastatin) or hydrophilic (pravastatin) and by potency as low potency (fluvastatin and lovastatin), medium potency (pravastatin), and high potency (simvastatin and atorvastatin) [19](#cam41368-bib-0019){ref-type="ref"}, [20](#cam41368-bib-0020){ref-type="ref"}.

Information on statin use was collected at baseline in the WHI, and thereafter follow‐up information on statin use was determined at year 3 in the OS participants and years 1, 3, 6, and 9 in the CT participants. At baseline and at each follow‐up visit, participants were asked to bring all of their current prescription medications to the clinic visit (or first interview at baseline). At those visits, interviewers entered each medication name directly from the medication containers into the WHI database, which assigned drug codes using Medispan software (First DataBank, Inc., San Bruno, CA). At the time of the visit, women also reported duration of statin use.

NHL {#cam41368-sec-0005}
---

Self‐report of NHL was locally verified at each clinic by medical record and pathology report review by centrally trained WHI physician adjudicators. Central adjudication and coding of histology were performed at the Clinical Coordinating Center using the Surveillance, Epidemiology, and End Results Program (SEER) coding system. Only NHL cases confirmed by central adjudication were included in the analysis (1091 cases). Information on subtype of NHL was available and included 368 cases of diffuse large B‐Cell lymphoma (DLBCL), 255 cases of follicular lymphoma, 96 cases of small lymphocytic lymphoma (SLL), and the rest were categorized as other lymphoma type. There were two cases where the diagnosis was not adjudicated and were not included in the analysis.

Covariates {#cam41368-sec-0006}
----------

Information on all covariates was collected at study entry including sociodemographic characteristics, clinical history as well as factors associated with healthcare utilization which might impact both statin utilization and detection or diagnosis of NHL.

Statistical analysis {#cam41368-sec-0007}
--------------------

The characteristics of statin users at baseline were compared with those of nonusers by chi‐squared tests. Annualized rates of NHL (incidence per person‐year) were calculated according to the use of statins. We performed selected subgroup analyses by information on duration of statin use (only available at baseline; \<1 year, 1--\<3 years, and ≥3 years), statin type, potency, and lipophilic status. Women who reported using two or more statins were included in analyses that compared statin use to none, but were excluded from analyses that examined details of statin use (by type, potency, or lipophilic status). Hazard ratios (HRs) for NHL among statin users versus nonusers, and 95% confidence intervals (CIs) were computed from Cox proportional hazards analyses. A Cox model that included statin use and the interaction of statin use with follow‐up time and testing for a zero coefficient on the interaction term was used to conduct tests for the proportional hazards assumptions.

While only 7.5% of WHI participants used statins at baseline, approximately 25% were using statins at the end of the trial completion. In order to account for increasing statin use during follow‐up, we examined the association of statin use and NHL using time‐dependent analyses. To evaluate the effect of change in statin use overtime, final models were run by entering statin use as a time‐dependent exposure and using updated information on statin use gathered at each follow‐up time point. Cases of NHL as well as noncases were censored if they occurred more than 3 years after last medication update in the OS participants to closely parallel the follow‐up experience of women in the CT. A set of covariates was selected a priori for adjustment of potential confounding based on covariates that are associated with risk of NHL or heathcare utilization. These included age (continuous), history of lupus and rheumatoid arthritis at WHI baseline (yes/no), and current medical care provider (at WHI baseline, yes/no). Additionally, all models included strata for age group at WHI enrollment, extension study (yes/no), and study group/trial participation.

Additional WHI baseline variables were individually tested as possible confounders: BMI, race/ethnicity, smoking status, education, percent energy from fats, recreational physical activity, waist circumference, aspirin use, history of cardiovascular diseases, and postmenopausal hormone use. We compared results from models that included all of the a priori covariates and each potential confounder to models including the a priori covariates only. Covariates were considered to be confounders if their inclusion in a model resulted in a change in any of the HRs for the statin variables by 10% or more. None of the additional variables met these criteria; therefore, the results presented are those from the models adjusted for the a priori covariates.

Separate analyses were conducted for individual subtypes of NHL (diffuse large B‐cell lymphoma (DLBCL), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), and follicular lymphoma).

Results {#cam41368-sec-0008}
=======

Table [1](#cam41368-tbl-0001){ref-type="table-wrap"} shows the baseline characteristics of statin users and nonusers. Statin users were more likely to be older, have a higher BMI and waist circumference, report having a healthcare provider, and to have more than 30% intake of energy from fat.

###### 

Baseline characteristics by statin use

                                     No        Yes                       
  ---------------------------------- --------- ------- --------- ------- ---------
  Age group at screening                                                 
  50--59                             51,368    34.35   2189      17.88   \<.0001
  60--69                             66,219    44.27   6370      52.03   
  70--79                             31,976    21.38   3684      30.09   
  Median age at screening            63 year           66 year           \<.0001
  Race/ethnicity                                                         
  White                              12,3494   82.57   10046     82.06   \<.0001
  Black                              13,499    9.03    1118      9.13    
  Hispanic                           6100      4.08    384       3.14    
  American Indian                    665       0.44    48        0.39    
  Asian/Pacific Islander             3720      2.49    470       3.84    
  Unknown                            2085      1.39    177       1.45    
  Education                                                              
  \<HS diploma/GED                   7850      5.29    794       6.53    \<.0001
  HS diploma/GED                     25,061    16.88   2563      21.07   
  \>HS diploma/GED                   115,517   77.83   8805      72.40   
  Smoking status                                                         
  Never                              75,545    51.18   5884      48.78   \<.0001
  Past                               61,667    41.77   5442      45.12   
  Current                            10,406    7.05    736       6.10    
  Alcohol                                                                
  Non drinker                        43,579    29.36   4221      34.70   \<.0001
  ≤1 drink/day                       48,774    32.86   4088      33.60   
  \>1 drink/day                      56,064    37.77   3856      31.70   
  Hormone therapy use                                                    
  Never                              65,272    43.68   5612      45.89   \<.0001
  Past                               23,760    15.90   2169      17.74   
  Current                            28,218    40.42   2222      36.37   
  Body mass index (kg/m^2^)                                              
  \<25                               53,313    35.96   3021      24.88   \<.0001
  25--\<30                           50,858    34.31   4822      39.72   
  ≥30                                44,068    29.73   4297      35.40   
  Median body mass index (kg/m^2^)   26.8              28.0              \<.0001
  Physical activity, met/wk                                              
  Inactive 0 METs                    22,703    15.94   1759      14.73   \<.0001
  \[0,3.75) METs                     20,789    14.60   1831      15.33   
  \[3.75, 8.75) METs                 29,140    20.46   2626      21.99   
  \[8.75, 17.5) METS                 32,101    22.54   2784      23.31   
  ≥17.5 METS                         37,660    26.45   2942      24.64   
  Waist circumference \>88 cm                                            
  No                                 91,023    61.08   6153      50.43   \<.0001
  Yes                                58,000    39/92   6049      49.57   
  ≥30% energy from fat                                                   
  No                                 52,486    35.16   5370      43.92   \<.0001
  Yes                                96,800    64.84   6856      56.08   
  Current healthcare provider                                            
  No                                 9800      6.62    195       1.61    \<.0001
  Yes                                138,286   93.38   11950     98.39   
  History of lupus                                                       
  No                                 146,729   99.50   12,133    99.59   0.1587
  Yes                                743       0.50    50        0.41    
  History of rheumatoid arthritis                                        
  No arthritis                       78,683    54.39   5484      45.99   \<.0001
  Rheumatoid arthritis               7185      4.97    686       5.75    
  Other arthritis/don\'t know        58,797    40.64   5754      48.26   
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Table [2](#cam41368-tbl-0002){ref-type="table-wrap"} shows the distribution of statin use at baseline by type, duration, potency, and lipophilicity. Simvastatin was the most common statin used with 29.3% of participants using it at baseline. The majority of statin users took lipophilic statins (69.4%) and 39.3% of users were on a statin classified as low potency, 38.2% high potency and 22.5% medium potency. Among statin users at baseline, the percentage of participants using statins for \<1 year, 1--\<3 years, and ≥=3 years was 33.1%, 33.9%, and 32.9%, respectively.

###### 

Distribution of statins by type, duration, and other statin characteristics

                                      No        Yes             
  ----------------------------------- --------- -------- ------ -------
  Statin type                                                   
  No statin use                       14,9563   100.00          
  Atorvastatin calcium                                   961    7.85
  Fluvastatin sodium                                     1484   12.12
  Lovastatin                                             3204   26.17
  Pravastatin sodium                                     2686   21.94
  Simvastatin                                            3589   29.31
  Two or more statins                                    319    2.61
  Statin potency                                                
  No statin use                       149,563   100.00          
  Low (Lovastatin, Fluvastatin)                          4688   39.32
  Medium (Pravastatin)                                   2686   22.53
  High (Simvastatin, Atorvastatin)                       4550   38.16
  Lipophilicity                                                 
  No statin use                       149,563   100.00          
  Lipophilic statins                                     8277   69.41
  Hydrophilic statins (pravastatin)                      3647   30.59
  Statin use in years                                           
  No statin use                       149,563   100.00          
  \<1                                                    4054   33.11
  1--\<3                                                 4151   33.91
  ≥3                                                     4038   32.98
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Table [3](#cam41368-tbl-0003){ref-type="table-wrap"} shows the relationship between baseline statin use and risk of NHL by overall statin use, statin type, potency, and lipophilicity. The annualized rate of NHL among statin users and nonusers was 0.06% and 0.05%, respectively, with a mean follow‐up of 12.57 years for statin users and 11.82 years for nonusers. Overall statin use at baseline was not associated with risk of NHL (HR 0.85, 95% C.I. 0.67--1.08). There was no significant association between statin lipophilicity, potency, type or duration of use, and risk of NHL.

###### 

Non‐Hodgkin\'s lymphoma (NHL) incidence (annualized %) and HRs by statin use

                                                                     Age adjusted   Multivariable adjusted                                      
  ---------------------------------- --------- ------ ------ ------- -------------- ------------------------ ------ ------ ------ ------ ------ ------
  Statin use                                                                                                                                    
  No                                 14,9338   1011   0.05   12.57   1.00                                           0.38   1.00                 0.18
  Yes                                12,225    80     0.06   11.82   0.90           0.72                     1.14   0.85   0.67   1.08          
  Statin type                                                                                                                                   
  No statin use                      14,9338   1011   0.05   12.57   1.00                                                  1.00                 
  Atorvastatin                       957       3      0.03   10.85   0.45           0.14                     1.39   0.16   0.45   0.14   1.40   0.17
  Fluvastatin                        1484      8      0.05   11.59   0.75           0.37                     1.50   0.41   0.65   0.31   1.38   0.26
  Lovastatin                         3197      24     0.06   12.25   1.01           0.67                     1.52   0.96   0.91   0.59   1.40   0.67
  Pravastatin                        2683      20     0.06   11.80   1.03           0.66                     1.60   0.90   0.94   0.59   1.51   0.81
  Simvastatin                        3585      22     0.05   11.82   0.86           0.56                     1.31   0.47   0.87   0.57   1.32   0.50
  Lipophilicity                                                                                                                                 
  No statin use                      14,9338   1011   0.05   12.57   1.00                                                  1.00                 
  Lipophilic                         9223      57     0.05   11.83   0.85           0.65                     1.11   0.24   0.80   0.61   1.06   0.13
  Hydrophilic                        2683      20     0.06   11.80   1.03           0.66                     1.60   0.90   0.94   0.59   1.51   0.81
  Statin potency                                                                                                                                
  No statin use                      14,9338   1011   0.05   12.57   1.00                                                  1.00                 
  Low (Lovastatin, Fluvastatin)      4681      32     0.06   12.04   0.93           0.65                     1.32   0.68   0.83   0.57   1.21   0.33
  Medium (Pravastatin)               2683      20     0.06   11.80   1.03           0.66                     1.60   0.90   0.94   0.59   1.51   0.81
  High (Simvastatin, Atorvastatin)   4542      25     0.05   11.62   0.77           0.52                     1.15   0.20   0.78   0.52   1.16   0.22
  Statin duration                                                                                                                               
  0                                  14,9338   1011   0.05   12.57   1.00                                                  1.00                 
  1--\<3 year                        4023      28     0.06   11.90   0.96           0.66                     1.39   0.82   0.87   0.59   1.30   0.50
  \<1 year                           3987      18     0.04   11.74   0.64           0.40                     1.02   0.06   0.58   0.35   0.95   0.03
  ≥3 year                            3896      31     0.07   11.84   1.08           0.75                     1.54   0.69   1.05   0.73   1.51   0.79

Stratified by trial, WHI extension study, and age group.

Base model was adjusted by age.

Multivariable model adjusted for age, history of lupus, history of rheumatoid arthritis, current medical care provider.
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Table [4](#cam41368-tbl-0004){ref-type="table-wrap"} shows the association of statin use and risk of NHL by overall statin use, statin type, potency, and lipophilicity using time‐dependent models. In the multivariable‐adjusted time‐dependent model, statin use was associated with a borderline significant lower risk of NHL compared to nonusers (HR 0.81, 95% C.I. 0.66--1.00) and in an analysis by statin lipophilicity, there was a suggestion of lower risk of NHL seen with use of lipophilic statins (HR 0.83, 95% C.I. 0.66--1.03). For hydrophilic statins, the HR for NHL was 0.76, 95% C.I. 0.49--1.22).

###### 

Non‐Hodgkin\'s lymphoma (NHL) HRs by time‐dependent statin use

                                           Age adjusted   Multivariable adjusted                                      
  ---------------------------------- ----- -------------- ------------------------ ------ ------ ------ ------ ------ ------
  Statin use                                                                                                          
  No                                 660   1.00                                                  1.00                 
  Yes                                53    0.82           0.68                     1.00   0.05   0.81   0.66   1.00   0.04
  Statin type                                                                                                         
  No statin use                      660   1.00                                                  1.00                 
  Atorvastatin calcium               2     0.81           0.60                     1.09   0.15   0.84   0.62   1.13   0.24
  Fluvastatin sodium                 6     0.66           0.31                     1.38   0.27   0.58   0.26   1.31   0.19
  Lovastatin                         17    1.09           0.66                     1.79   0.74   1.00   0.59   1.70   0.99
  Pravastatin sodium                 11    0.79           0.49                     1.29   0.35   0.79   0.48   1.30   0.36
  Simvastatin                        15    0.88           0.62                     1.24   0.46   0.85   0.59   1.22   0.37
  Lipophilicity                                                                                                       
  No statin use                      660   1.00                                                  1.00                 
  Lipophilic statin                  40    0.84           0.68                     1.04   0.11   0.83   0.66   1.03   0.09
  Hydrophilic statin                 11    0.77           0.50                     1.21   0.26   0.76   0.49   1.22   0.28
  Statin potency                                                                                                      
  No statin use                      660   1.00                                                  1.00                 
  Low (Lovastatin, Fluvastatin)      23    0.89           0.58                     1.35   0.57   0.81   0.52   1.26   0.34
  Medium (Pravastatin)               11    0.78           0.48                     1.26   0.30   0.77   0.47   1.27   0.31
  High (Simvastatin, Atorvastatin)   17    0.83           0.65                     1.04   0.11   0.83   0.65   1.06   0.13

Stratified by trial, WHI extension study, and age group.

Base model was adjusted by age.

Multivariable model adjusted for age, current medical care provider, history of lupus, history of rheumatoid arthritis.
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Table [5](#cam41368-tbl-0005){ref-type="table-wrap"} shows the time‐dependent multivariable‐adjusted relationship between statin use and risk of NHL by histologic subtype. Statin use was associated with a reduced risk of DLBCL (HR 0.62, 95% C.I. 0.42--0.91). This effect was mostly driven by lipophilic statins (HR 0.62, 95% C.I. 0.40--0.96). No association was seen between risk of DLBCL and statin potency or individual statin type. There was no significant relationship between statins and risk of follicular lymphoma (HR 0.96, 95% C.I. 0.64--1.43), marginal zone lymphoma (HR 0.76, 95% C.I. 0.39--1.46), or SLL (HR 0.98, 95% C.I. 0.72--1.34).

###### 

Diffuse large B‐Cell lymphoma (DLBCL) HRs by time‐dependent statin use

                                           Age adjusted   Multivariable adjusted                                        
  ---------------------------------- ----- -------------- ------------------------ ------ ------ ------- ------- ------ ------
  Statin use                                                                                                            
  No                                 215   1.00                                           0.02   1.00                   0.02
  Yes                                13    0.65           0.45                     0.94   0.62   0.42    0.91           
  Statin type                                                                                                           
  No statin use                      215   1.00                                                  1.00                   
  Atorvastatin                       1     0.69           0.40                     1.19   0.18   0.69    0.39    1.23   0.21
  Fluvastatin                        1     0.26           0.04                     1.89   0.18   0.000   0.000          0.97
  Lovastatin                         2     0.59           0.19                     1.83   0.36   0.63    0.20    1.98   0.43
  Pravastatin                        5     0.68           0.28                     1.65   0.40   0.58    0.22    1.58   0.29
  Simvastatin                        4     0.83           0.45                     1.52   0.54   0.81    0.43    1.54   0.53
  Lipophilicity                                                                                                         
  No statin use                      215   1.00                                                  1.00                   
  Lipophilic                         8     0.65           0.43                     0.97   0.04   0.62    0.40    0.96   0.03
  Hydrophilic                        5     0.79           0.37                     1.67   0.53   0.72    0.32    1.63   0.43
  Statin potency                                                                                                        
  No statin use                      215   1.00                                                  1.00                   
  Low (Lovastatin, Fluvastatin)      3     0.44           0.16                     1.18   0.10   0.35    0.11    1.10   0.07
  Medium (Pravastatin)               5     0.67           0.27                     1.62   0.37   0.57    0.21    1.54   0.27
  High (Simvastatin, Atorvastatin)   5     0.74           0.48                     1.12   0.15   0.73    0.47    1.14   0.16

Stratified by trial, WHI extension study, and age group.

Base model was adjusted by age.

Multivariable model adjusted for age, current medical care provider, history of lupus, history of rheumatoid arthritis.
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Discussion {#cam41368-sec-0009}
==========

We analyzed the association of statins and risk of NHL over a long period of follow‐up and showed in a time‐dependent analysis that statin use was associated with a borderline lower risk of NHL. Furthermore, we found that statin use is specifically associated with a statistically significant lower risk of DLBCL. The inverse association with statins was restricted to lipophilic statins, but an association with other statins cannot be ruled out. It is also possible that the results may be due to residual confounding.

Table [6](#cam41368-tbl-0006){ref-type="table-wrap"} includes an outline of longitudinal studies evaluating the relationship between statin use and NHL risk. Our findings are supported by the results of three other studies demonstrating a reduced risk of NHL among statin users [8](#cam41368-bib-0008){ref-type="ref"}, [9](#cam41368-bib-0009){ref-type="ref"}, [10](#cam41368-bib-0010){ref-type="ref"}; however, two other studies reported no significant impact of statins [11](#cam41368-bib-0011){ref-type="ref"}, [12](#cam41368-bib-0012){ref-type="ref"}. In an analysis of the Cancer Prevention Study II Nutrition Cohort (CPS‐II), Jacobs et al. demonstrated that statin use for five or more years was associated with a reduction in risk of several cancers including NHL overall (HR = 0.74, 95% CI 0.62--0.89) as well as DLCL (RR = 0.68, 95% CI 0.46--1.00) and marginal zone lymphoma (RR = 0.36, 95% CI 0.15--0.86) [9](#cam41368-bib-0009){ref-type="ref"}. In a case--control study nested in a cohort of 547 UK general practices, comprising of 7285 cases of hematologic malignancies (including lymphoma, myeloma, and leukemia), Vinogradova et al. [10](#cam41368-bib-0010){ref-type="ref"} reported that ever use of statins was associated with a reduced risk (HR = 0.78, 95% CI 0.71--0.86). Lastly in the EPI‐LYMPH case--control study comprising 2362 cases of incident lymphomas and 2206 controls, ever use of a statin was associated with a lower risk of lymphoma (OR 0.61, 95% C.I. 0.45--0.84) [8](#cam41368-bib-0008){ref-type="ref"}. In contrast, a U.S. case--control study of 4913 cancer cases, of which 144 were NHL cases, did not result in a reduction in risk of lymphoma [12](#cam41368-bib-0012){ref-type="ref"} while a Japanese case--control with 221 cases showed an increased risk of lymphoma associated with statins (OR 2.11, 95% CI 1.20--3.69) [11](#cam41368-bib-0011){ref-type="ref"}. Our analysis was only the second cohort study to look at the relationship between statins and lymphoma risk. While in contrast to others, our study only included women by design, we had a larger cohort size than the Jacobs et al. study, however, fewer cases of NHL. In addition, as were others, we were able to analyze the relationship of statin subtype with NHL risk. Our results, however, were comparable to Jacob\'s et al. showing a lower risk of DLBCL. We, however, did not see a significant reduction in marginal zone lymphoma.

###### 

Longitudinal studies of stains and risk of non‐Hodgkin\'s lymphoma (NHL)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref                                                       Study type               Sample size                    Exposure                                      Outcome                                                           HR, 95% CI
  --------------------------------------------------------- ------------------------ ------------------------------ --------------------------------------------- ----------------------------------------------------------------- --------------------
  Jacobs [9](#cam41368-bib-0009){ref-type="ref"}            Cohort                   Cases: 1005\                   Current \< or \> 5 years                      NHL\                                                              0.74 (0.62--0.86)\
                                                                                     Pop: 133, 255                                                                DLCL                                                              0.68 (0.46--1.00)

  Desai                                                     Cohort                   Cases: 712\                    Current \< or \> 3 years and time dependent   NHL\                                                              0.81 (0.66--0.99)\
                                                                                     Pop: 161,563                                                                 Lipophilic statins\                                               0.82 (0.66--1.03)\
                                                                                                                                                                  DLCL                                                              0.61 (0.41--0.91)

  Vingradova [10](#cam41368-bib-0010){ref-type="ref"}       1 Nested Case--Control   Cases of heme cancers: 7185\   Statin yes vs. no                             Hematologic Malignancies (including leukemia, myeloma, and NHL)   0.61 (0.41--0.89)
                                                                                     Controls: 29,162                                                                                                                               

  Epilymph study [11](#cam41368-bib-0011){ref-type="ref"}   Case--Control            Cases‐2362\                    Ever use of statins                           NHL (B, T, and NK)                                                0.61 (0.41--0.89)
                                                                                     Controls: 2206                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Results from a number of preclinical studies suggest that our current observation is biologically plausible. Statins have been previously shown to have chemopreventive effects for a large number of cancer types based on their downstream molecular effects [21](#cam41368-bib-0021){ref-type="ref"}, [22](#cam41368-bib-0022){ref-type="ref"}. Reports examining the in vitro impact of statins have shown that statins possess antiproliferative, apoptotic, and anti‐invasive properties resulting from their ability to target multiple signaling pathways within malignant cells [21](#cam41368-bib-0021){ref-type="ref"}, [22](#cam41368-bib-0022){ref-type="ref"}, [23](#cam41368-bib-0023){ref-type="ref"}, [24](#cam41368-bib-0024){ref-type="ref"}, [25](#cam41368-bib-0025){ref-type="ref"}, [26](#cam41368-bib-0026){ref-type="ref"}, [27](#cam41368-bib-0027){ref-type="ref"}, [28](#cam41368-bib-0028){ref-type="ref"}, [29](#cam41368-bib-0029){ref-type="ref"}. Statins have been shown to reduce the farnesylation of Ras needed for its attachment to the cellular membrane [23](#cam41368-bib-0023){ref-type="ref"}, and Ras is involved in many intracellular pathways and has been shown to increase gene transcription and proliferation via MEK and PI3K/Akt signaling [21](#cam41368-bib-0021){ref-type="ref"}.

Statins have also been shown to inhibit the production of FPP and GPPP, two key downstream products involved in posttranslational modification of many proteins including geranylgeranylation of Rho proteins (Rho GTPases) [30](#cam41368-bib-0030){ref-type="ref"}. In turn, these gene products regulate Rho kinases, which are involved in various cellular functions including gene expression, actin cytoskeleton migration, adhesion, and contractility of cells [31](#cam41368-bib-0031){ref-type="ref"}. Thus, by inhibiting the production of GGPP, statins may have antiproliferative and anti‐invasive properties. Statins have also been implicated in G1‐S arrest [32](#cam41368-bib-0032){ref-type="ref"}. Lastly, studies using transgenic mouse models have demonstrated that statins possess proapoptotic and antitumor activity against lymphoma [5](#cam41368-bib-0005){ref-type="ref"}. Data from Ajith et al. indicate that statin‐induced apoptosis depends on their ability to inhibit lipid peroxidation and depleted key geranylgeranylated proteins. Shachaf et al. have described a transgenic mouse model in which atorvastatin reverses the development of MYC‐induced lymphomas in a dose‐dependent fashion [6](#cam41368-bib-0006){ref-type="ref"}. In this latter model, atorvastatin was found to delay the onset of lymphoma, helping to purge neoplastic cells from the bone marrow. These effects were negated if Ras was constitutively activated. The specific pathway by which statins exert this effect is by inactivating MYC following disruption of upstream Ras/ERK ½ pathways.

Another mechanism by which statins may impact risk of lymphoma is through inhibition of histone deacetylases (HDACs). It has been recently shown that the carboxylic moiety of lovastatin can bind and chelate the catalytic site of HDAC2, leading to increased p21 expression and inhibition of tumor cell growth [33](#cam41368-bib-0033){ref-type="ref"}. HDAC inhibition has been targeted in a number of hematologic malignancies including lymphoma [34](#cam41368-bib-0034){ref-type="ref"}. Lastly, the anti‐inflammatory effect of statins may be an important mechanism of reduction in risk of lymphoma as chronic inflammation is a possible risk factor for lymphoma [7](#cam41368-bib-0007){ref-type="ref"}.

Our observation that statins differentially impact lymphoma risk based on their biologic properties is also consistent with the exiting medical literature \[[21](#cam41368-bib-0021){ref-type="ref"}, 35\]. Statins are classified according to their solubility in octanol (lipophilicity) and water (hydrophilicity) [16](#cam41368-bib-0016){ref-type="ref"}. Lipophilic statins (lovastatin, simvastatin fluvastatin, and atorvastatin) penetrate the plasma member while hydrophilic statins (pravastatin) do not. A number of in vitro studies have shown that lipophilic statins possess the most robust anticancer properties, consistent with the observations reported above.

The strengths of our analysis include the prospective design, the large diverse population with detailed demographic characterization, adjudicated cancer diagnosis by central review, serial update of statin use, and long follow‐up period. The comprehensive data collection in the WHI also allows for a detailed adjustment for confounding variables. Limitations include the observational nature and the relatively low prevalence of statin use at baseline among WHI subjects. Despite these limitations, we were able to capture updated information on statin use using a time‐dependent analysis. Another limitation is the lack of data documenting medication compliance and HIV status, another risk factor for NHL. It is currently thought that the prevalence of HIV in the WHI cohort of postmenopausal women is low. We also did not have dose information on statins and were not able to analyze relationship of dosing or duration of use in the time‐dependent analysis. Our results suggesting a relationship between lipophilic statins and NHL may be particularly important for high‐risk populations such as those with autoimmune conditions. Our findings showing a specific impact on DLBCL have implications for future studies of the impact of statins on risk of recurrent disease.

Conclusion {#cam41368-sec-0010}
==========

Statin use may be associated with a lower risk of NHL in women particularly DLBCL. These results should be evaluated in other large datasets, particularly meta‐analyses of trial data, with a particular emphasis on specific type of NHL.
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